Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), announced the completion of enrollment in the COMPASS study, a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE